A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity

Toxicology and Applied Pharmacology

Volumn 145, Issue 2, 1997, Pages 301-310

  Hissink, A M ^a,b   Van Ommen, B ^a   Kruse J ^a   Van Bladeren, P J ^a  

^a TNO   (Netherlands)

^b Utrecht Toxicological Center (UTOX)   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DICHLOROBENZENE; GLUTATHIONE;

ANIMAL EXPERIMENT; ARTICLE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; LIVER TOXICITY; METABOLITE; MODEL; NONHUMAN; PARTITION COEFFICIENT; RAT; TOXICOKINETICS; XENOBIOTIC METABOLISM;

ANIMALIA;

EID: 0031214663     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8184     Document Type: Article

References (35)

1. Bäärnhielm C., Dahlbäck H., Skanberg I. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacol. Toxicol. 59:1986;113-122.
2. Biaglow J. E., Varnes M. E., Roizen-Towle L., Clark E. P., Epp E. R., Astor M. B., Hall E. J. Biochemistry of reduction of nitro heterocycles. Biochem. Pharmacol. 35:1986;77-90.
3. Bogaards J. J. P., Van Ommen B., Wolf C. R., Van Bladeren P. J. Human cytochrome P450 enzyme selectivities in the oxidation of chlorinated benzenes. Toxicol. Appl. Pharmacol. 132:1995;44-52.
4. Cameron G. R., Thomas J. C., Ashmore S. A., Buchan J. L., Warren E. H., McKenny Hughes A. W. The toxicity of certain chlorine derivatives of benzene, with special reference too. J. Pathol. Bacteriol. 44:1937;281-296.
5. Corley R. A., Mendrala A. L., Smith F. A., Staats D. A., Gargas M. L., Conolly R. B., Andersen M. E., Reitz R. H. Development of a physiologically-based pharmacokinetic model for chloroform. Toxicol. Appl. Pharmacol. 103:1990;512-527.
6. Dedrick R. L. Animal scale-up. J. Pharmacokinet. Biopharm. 1:1973;435-461.
7. Den Besten C., Vet J. J. R. M., Besselink H. T., Keil G. S., Van Berkel J. M., Beems R., Van Bladeren P. J. The liver, kidney and thyroid toxicity of chlorinated benzenes. Toxicol. Appl. Pharmacol. 111:1991;69-81.
8. Droz P. O., Wu M. M., Cumberland W. G., Berode M. Variability in biological monitoring of solvent exposure. I. Development of a population physiological model. Br. J. Ind. Med. 46:1989;447-460.
9. D'Souza R. W., Andersen M. E. Physiologically based pharmacokinetic model for vinylidene chloride. Toxicol. Appl. Pharmacol. 95:1988;230-240.
10. Fiserova-Bergerova V. Physiological models for pulmonary administration and elimination of inert vapors and gases. Modeling of Inhalation Exposure to Vapors: Uptake, Distribution and Elimination. 1983;CRC Press, Boca Raton. p. 101-132.
11. Frederick C. B., Potter D. W., Chang-Mateu M. I., Andersen M. E. A physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. Toxicol. Appl. Pharmacol. 114:1992;246-260.
12. Gargas M. L., Andersen M. E., Clewell H. J. III. A physiologically based simulation approach for determining metabolic constants from gas uptake data. Toxicol. Appl. Pharmacol. 86:1986;341-352.
13. Gargas M. L., Andersen M. E. A gas phase technique for determining the kinetic constants of chemical metabolism in the rat. Toxicologist. 8:1988.
14. Gunawardhana L., Mobley S. A., Sipes I. G. Modulation of 1,2-dichlorobenzene hepatotoxicity in the Fischer-344 rat by a scavenger of superoxide anions and an inhibitor of Kupffer cells. Toxicol. Appl. Pharmacol. 119:1993;205-213.
15. Hissink A. M., Van Ommen B., Van Bladeren P. J. Dose dependent kinetics and metabolism of 1,2-dichlorobenzene in rats: effect of pretreatment with phenobarbital. Xenobiotica. 26:1996;89-105.
16. Hissink A. M., Oudshoorn M. J., Van Ommen B., Van Bladeren P. J. Differences in cytochrome P450-mediated biotransformation of 1,2-dichlorobenzene by rat and man: Implications for human risk assessment. Chem. Res. Tox. 9:1996;1249-1256.
17. Hollingsworth R. L., Rowe V. K., Oyen F., Torkelson T. R., Adams E. M. Toxicity ofo. Arch. Ind. Health. 17:1958;180-187.
18. Houston J. B. Utility ofin vitroin vivo. Biochem. Pharmacol. 47:1994;1469-1479.
19. Kedderis G. L., Carfagna M. A., Held S. D., Batra R., Murphy J. E., Gargas M. L. Kinetic analysis of furan biotransformation by F-344 ratsin vivoin vitro. Toxicol. Appl. Pharmacol. 123:1993;274-282.
20. Kumagai S., Matsunaga I. Effect of variation of exposure to airborne chlorobenzene on internal exposure and concentrations of urinary metabolite. Occup. Environ. Med. 52:1995;65-70.
21. Medinsky M. A., Sabourin P. J., Lucier G., Birnbaum L. S., Henderson R. F. A physiological model for simulation of benzene metabolism by rats and mice. Toxicol. Appl. Pharmacol. 99:1989;193-206.
22. Mes J., Davies D. J., Turton D., Sun W. F. Levels and trends of chlorinated hydrocarbon contaminants in the breast milk of Canadian women. Food Add. Contam. 3:1986;313-322.
23. Oliver B. G., Nicol K. D. Chlorobenzenes in sediments, water, and selected fish from lakes Superior, Huron, Erie, and Ontario. Environ. Sci. Technol. 16:1982;532-536.
24. Perella F. W. EZ-FIT: A practical curve-fitting microcomputer program for the analysis of enzyme kinetic data on IBM-PC compatible computers. Anal. Biochem. 174:1988;437-447.
25. Potter D. W., Tran T. Apparent rates of glutathione turnover in rat tissues. Toxicol. Appl. Pharmacol. 120:1993;186-192.
26. Ramsey J. C., Andersen M. E. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73:1984;159-175.
27. W. D. Reid, 1972, Relationship between tissue necrosis and covalent binding of toxic metabolites of halogenated aromatic hydrocarbons, Pharmacology and the Future of Man, 2, 62, 74.
28. Reitz R. H., Mendrala A. L., Guengerich F. P. In vitro. Toxicol. Appl. Pharmacol. 97:1989;230-246.
29. Reitz R. H., Gargas M. L., Mendrala A. L., Schumann A. M. In vivoin vitro. Toxicol. Appl. Pharmacol. 136:1996;289-306.
30. Robinson M., Bercz J. P., Ringhand H. P., Condie L. W., Parnell M. J. Ten- and ninety-day toxicity studies of 1,2-dichlorobenzene administered by oral gavage to Sprague-Dawley rats. Drug Chem. Toxicol. 14:1991;83-112.
31. Stine E. R., Gunawardhana L., Sipes I. G. The acute hepatotoxicity of the isomers of dichlorobenzene in Fischer-344 and Sprague-Dawley rats: Isomer-specific and strain-specific differential toxicity. Toxicol. Appl. Pharmacol. 109:1991;472-481.
32. U.S. EPA, 1985, Health Assessment Document for Chlorinated Benzenes, Office of Health and Environmental Assessment, Washington, DC.
33. Valentovic M. A., Ball J. G., Anestis D., Madan E. Modification of P450 activity and its effect on 1,2-dichlorobenzene toxicity in Fischer-344 rats. Toxicology. 79:1993;169-180.
34. Vinegar A., Williams R. J., Fisher J. W., McDougal J. N. Dose-dependent metabolism of 2,2-dichloro-1,1,1-trifluoroethane: A physiologically based pharmacokinetic model in the male Fischer 344 rat. Toxicol. Appl. Pharmacol. 129:1994;103-113.
35. Yeung J. H., Chiu L. C., Ooi V. E. Effect of polysaccharide peptide (PSP) on glutathione and protection against paracetamol-induced hepatotoxicity in the rat. Methods Find. Exp. Clin. Pharmacol. 16:1994;723-729.